scholarly journals Neuronal inclusions of α-synuclein contribute to the pathogenesis of Krabbe disease

2014 ◽  
Vol 232 (5) ◽  
pp. 509-521 ◽  
Author(s):  
Benjamin R Smith ◽  
Marta B Santos ◽  
Michael S Marshall ◽  
Ludovico Cantuti-Castelvetri ◽  
Aurora Lopez-Rosas ◽  
...  
2015 ◽  
Vol 46 (S 01) ◽  
Author(s):  
A. Bley ◽  
U. Löbel ◽  
M. Nickel ◽  
A. Ohlenbusch ◽  
J. Denecke ◽  
...  

2008 ◽  
Vol 39 (01) ◽  
Author(s):  
U Gruber-Sedlmayr ◽  
M Brunner-Krainz ◽  
E Sorantin ◽  
W Sauseng ◽  
B Plecko

Author(s):  
Robert Thompson-Stone ◽  
Margie A. Ream ◽  
Michael Gelb ◽  
Dietrich Matern ◽  
Joseph J. Orsini ◽  
...  

2021 ◽  
Vol 7 (2) ◽  
pp. 28
Author(s):  
Camille S. Corre ◽  
Dietrich Matern ◽  
Joan E. Pellegrino ◽  
Carlos A. Saavedra-Matiz ◽  
Joseph J. Orsini ◽  
...  

Krabbe disease (KD) is a rare inherited neurodegenerative disorder caused by a deficiency in galactocerebrosidase enzyme activity, which can present in early infancy, requiring an urgent referral for hematopoietic stem cell transplantation, or later in life. Newborn screening (NBS) for KD requires identification and risk-stratification of patients based on laboratory values to predict disease onset in early infancy or later in life. The biomarker psychosine plays a key role in NBS algorithms to ascertain probability of early-onset disease. This report describes a patient who was screened positive for KD in New York State, had a likely pathogenic genotype, and showed markedly reduced enzyme activity but surprisingly low psychosine levels. The patient ultimately developed KD in late infancy, an outcome not clearly predicted by existing NBS algorithms. It remains critical that psychosine levels be evaluated alongside genotype, enzyme activity levels, and the patient’s evolving clinical presentation, ideally in consultation with experts in KD, in order to guide diagnosis and plans for monitoring.


Biomedicines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 560
Author(s):  
An Cheng ◽  
Wenbin Jia ◽  
Ichiro Kawahata ◽  
Kohji Fukunaga

Synucleinopathies are diverse diseases with motor and cognitive dysfunction due to progressive neuronal loss or demyelination, due to oligodendrocyte loss in the brain. While the etiology of neurodegenerative disorders (NDDs) is likely multifactorial, mitochondrial injury is one of the most vital factors in neuronal loss and oligodendrocyte dysfunction, especially in Parkinson’s disease, dementia with Lewy body, multiple system atrophy, and Krabbe disease. In recent years, the abnormal accumulation of highly neurotoxic α-synuclein in the mitochondrial membrane, which leads to mitochondrial dysfunction, was well studied. Furthermore, fatty acid-binding proteins (FABPs), which are members of a superfamily and are essential in fatty acid trafficking, were reported to trigger α-synuclein oligomerization in neurons and glial cells and to target the mitochondrial outer membrane, thereby causing mitochondrial loss. Here, we provide an updated overview of recent findings on FABP and α-synuclein interactions and mitochondrial injury in NDDs.


2010 ◽  
Vol 89 (3) ◽  
pp. 352-364 ◽  
Author(s):  
A.B. White ◽  
F. Galbiati ◽  
M.I. Givogri ◽  
A. Lopez Rosas ◽  
X. Qiu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document